ALS drug development: reflections from the past and a way forward
about
Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic TrialsBlood-CNS Barrier Impairment in ALS patients versus an animal modelAlzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and GammaPredicting Speech Intelligibility Decline in Amyotrophic Lateral Sclerosis Based on the Deterioration of Individual Speech Subsystems.Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis.Targeting Abeta and tau in Alzheimer's disease, an early interim reportThe application of biomarkers in clinical trials for motor neuron diseaseUtility of dissociated intrinsic hand muscle atrophy in the diagnosis of amyotrophic lateral sclerosisChemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanomaAstroglial inhibition of NF-κB does not ameliorate disease onset and progression in a mouse model for amyotrophic lateral sclerosis (ALS)Riluzole increases the rate of glucose transport in L6 myotubes and NSC-34 motor neuron-like cells via AMPK pathway activation.Human pluripotent stem cells: applications and challenges in neurological diseases.Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications.Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALSAn overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders.New therapeutic targets for amyotrophic lateral sclerosis.How can we improve clinical trials in amyotrophic lateral sclerosis?Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis.Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease.Potential new complication in drug therapy development for amyotrophic lateral sclerosis.Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models.Improving access to medicines: empowering patients in the quest to improve treatment for rare lethal diseases.The voltage-gated calcium channel blocker lomerizine is neuroprotective in motor neurons expressing mutant SOD1, but not TDP-43.A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis
P2860
Q26742196-0CA608B6-F99E-479F-B4FE-42BAD8A820FBQ27021917-B87FC056-8B96-4F55-B375-58D114C27BF5Q27026792-BB3D50F4-A694-438C-87C5-B825C4D61982Q28075617-DAEAB3B0-6ADF-417C-B8A0-2A962D34D23EQ30383800-CFDBB349-283A-4595-BE70-795E7F72719AQ33791649-A24DF0F2-5F55-4720-82DD-35AD8C365C1BQ33829008-8A59F4E1-6A83-41E0-95F6-44A2E43FF461Q33961751-AC0401FC-A03C-4670-908C-2E456E6C3BE4Q34009478-073A81DC-D0A8-4CC5-90EC-FFA9A35AE21AQ34603059-EE449B7F-A7E7-4FBB-808B-347FF32C2A70Q34698706-CD5108A2-A257-48C6-AE27-F35E7CD9447EQ34802341-B3AD02DB-9ED6-4FF6-8A19-29734B1D9310Q36193696-935FFF19-0FA6-4AE3-966D-F66D716AF4A6Q36232627-573C4E12-9EDC-4C94-B69E-CD3239316223Q37393810-F0AC9521-80BE-4F3F-B610-9300F8D65929Q37733587-6E2D5906-B365-412E-8878-B557E72D07CCQ37816447-C0529485-59BB-4F9A-A72A-3F3F2AFD9605Q37938694-CAE2A2A4-6979-47B7-9719-62E4250A169FQ37952528-89359EC9-3EC7-49AD-8A94-E75AD59B1D52Q38796845-819DAF2B-B0FB-4366-96ED-5B275387C14FQ38881707-4423AFB6-C48B-4340-85E4-1AFB799A3A15Q44692126-C524E287-3F10-48DC-BCC2-F8ACC000AACAQ47870601-CB5B09CC-5BAB-4D3D-AE8D-343DF0EC8CCFQ52649242-72133082-9099-40AF-9746-F7B3D1AF114FQ57666978-11FCB8BF-AFBB-45B7-9F34-6855403475D7
P2860
ALS drug development: reflections from the past and a way forward
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ALS drug development: reflections from the past and a way forward
@en
ALS drug development: reflections from the past and a way forward.
@nl
type
label
ALS drug development: reflections from the past and a way forward
@en
ALS drug development: reflections from the past and a way forward.
@nl
prefLabel
ALS drug development: reflections from the past and a way forward
@en
ALS drug development: reflections from the past and a way forward.
@nl
P2860
P1433
P1476
ALS drug development: reflections from the past and a way forward
@en
P2093
Swati Aggarwal
P2860
P2888
P304
P356
10.1016/J.NURT.2008.08.002
P577
2008-10-01T00:00:00Z
P5875
P6179
1006957495